Total Funding
93
70
Total FundingPost-IPO Equity raised
Growth Score
10 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
20445
Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Carmine Stengone: President & CEOPast Role: COI Pharmaceuticals, SVP, Business Development
Peter Slover: Chief Financial OfficerPast Role: Sophiris Bio, CFO
About the Company
Contineum Therapeutics is a clinical-stage biopharmaceutical company that pioneers oral small-molecule therapies for neuroscience, inflammation, and immunology. The company focuses on addressing high unmet needs in these areas, targeting specific biological pathways to impact disease progression. With a pipeline of internally developed programs,
including PIPE-791 and PIPE-307, it aims to revolutionize treatment for disorders like idiopathic pulmonary fibrosis and multiple sclerosis.
